Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The Company has initiated a pivotal trial of its lead product candidate, SGN-35, for patients with relapsed or refractory Hodgkin lymphoma under a special protocol assessment (SPA) with the United States Food and Drug Administration (FDA). SGN-35 is empowered by its antibody-drug conjugate (ADC) technology comprising synthetic drugs and linkers for attaching the drugs to monoclonal antibodies. In addition, the Company has three other product candidates in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech, Inc.